PA8.F Paion AG (XETRA) rises 1,313.33% intraday on 02 Feb 2026: monitor liquidity

PA8.F stock jumped 1,313.33% intraday to EUR 0.848 on XETRA on 02 Feb 2026, driven by a thin order book and heavy relative volume. The move followed an open at EUR 0.848 versus a previous close of EUR 0.06, producing a surge in trading activity with 4,600 shares changing hands so far. Traders should note the stock’s low free float and the healthcare sector’s muted 1‑day move of +1.05%, which shows this spike is idiosyncratic rather than sector‑wide.

PA8.F stock: Intraday move and drivers

The main driver of the intraday gain is shallow liquidity and a gap between the previous close and today’s orders; price moved from EUR 0.06 to EUR 0.848. One block trade and short‑term speculative flows appear responsible rather than a clinical or regulatory update from Paion AG. We see a relative volume of 21.10x versus the 50‑day average, confirming concentrated buying pressure.

Valuation and financials for Paion AG (PA8.F) on XETRA

At market cap EUR 612,071.00 and shares outstanding 7,133,700, Paion’s reported metrics look distorted by the price swing. Key ratios: price/sales 0.02, EV/EBITDA 0.14, and a trailing PE shown as -1.06 due to negative net income per share. Revenue per share is 4.66 and net income per share is -0.08, highlighting a small revenue base but persistent losses.

Technical, liquidity and trading metrics

Technically the stock opened at EUR 0.848 and reached a day high of EUR 0.85 on unusually low absolute volume. Average volume is 850 shares, so today’s 4,600 shares equal a 21.10x jump in flow. Short‑term volatility and the tight bid‑ask will likely produce fast retracements if selling interest emerges.

Meyka AI rates PA8.F with a score out of 100

Meyka AI rates PA8.F with a score out of 100: 58.75 (C+) — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The C+ reflects elevated volatility, small market cap (EUR 612,071.00), modest revenue per share, and no clear earnings runway.

Meyka AI’s forecast model projects and price targets

Meyka AI’s forecast model projects a monthly target of EUR 0.020, which compared with the current price EUR 0.848 implies a model‑based downside of -97.64%. For trading context we show a conservative 12‑month reference price target of EUR 0.05 (analyst‑style scenario), implying -94.11% versus today. Forecasts are model‑based projections and not guarantees.

Risks, opportunities and sector context

Upside opportunity is limited without a material corporate catalyst such as licensing or clinical news; downside risk is high because the stock is micro‑cap, thinly traded, and in the Healthcare sector where peers show steadier fundamentals. Paion AG operates in Drug Manufacturers – Specialty & Generic, where average 1‑day sector change is +1.05%, so this move is company specific.

Final Thoughts

Key takeaways for PA8.F stock traders: the intraday spike to EUR 0.848 on 02 Feb 2026 is driven by extremely low liquidity and concentrated orders rather than confirmed corporate news. Volume of 4,600 versus an average 850 signals short‑term momentum but not sustainable buying. Valuation metrics show a tiny market cap (EUR 612,071.00) and distorted ratios — price/sales 0.02 and negative EPS — so fundamentals do not support the current level absent a credible catalyst. Meyka AI’s models project EUR 0.020 in one month and offer a conservative 12‑month reference target of EUR 0.05, implying steep downside versus today; forecasts are model‑based and not guarantees. Traders should prioritise liquidity, use limit orders, and treat PA8.F as a high‑risk, speculative position given the company’s small capitalization and volatile trading profile. For company details visit Paion AG website and check live quotes on our Meyka platform: Meyka PA8.F page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.